Association of K-ras codon 12 transversions with short survival in non-small cell lung cancer

International Journal of Oncology

Volumn 9, Issue 6, 1996, Pages 1307-1311

  Vega, Francisco J ^a   Iniesta, Pilar ^a   Caldés, Trinidad ^b   Sanchez, Andrés ^b   Lopez, Jose A ^b   De Juan, Carmen ^a   Diaz Rubio, Eduardo ^b   Torres, Antonio ^b   Balibrea, Jose L ^b   Benito, Manuel ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

K ras; NSCLC; survival; transversion

Indexed keywords

ADULT; AGED; ARTICLE; FEMALE; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; ONCOGENE K RAS; PRIORITY JOURNAL; SURVIVAL;

EID: 0029805521     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.9.6.1307     Document Type: Article

References (26)

1. Boring CC, Squires TS and Tong T: Cancer Statistics. CA Cancer J Clin 44: 7-26, 1993.
2. Minna JD, Pass H, Glatstein E and Ihde DC: Lung cancer. In: Cancer: Principles and Practice of Oncology. De Vita VT Jr, Hellman S and Rosenberg SA (eds). PA Lippincot, Philadelphia, pp591-705, 1989.
3. Travis WD, Travis LB and Devesa SS: Lung cancer. Cancer 75: 191-202, 1995.
4. Minna JD: The molecular biology of lung cancer pathogenesis. Chest (Suppl) 103: 449-456, 1993.
5. Greenblatt MS, Bennet WP, Hollstein M and Harris CC: Mutations in the p53 tumor suppessor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878, 1994.
6. Kiaris H and Spandidos DA: Mutations of K-ras genes in human tumours. Int J Oncol 7: 413-421, 1995.
7. Buchhagen DL: Molecular mechanisms in lung pathogenesis. Biochim Biophys Acta 1072: 159-176, 1991.
8. Barbacid M: Ras genes. Annu Rev Biochem 56: 779-827, 1987.
9. Sistonen L and Alitalo K: Activation of c-ras oncogenes by mutations and amplification. Ann Clin Res 18: 297-303, 1986.
10. Mitsudomi T, Viallet J, Linnoila I, Minna JD and Gazdar AF: Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell line from small-cell lung cancer cell lines. Oncogene 6: 1353-1362, 1991.
11. Slebos RJC, Kibbelaar RE, Dalesio O, Kooistra A, Stam A, Meijer CJL, Wagenaar SS, Vanderschueren RGJRA, Zandwijk NV, Mooi WJ, Bos JL and Rodenhuis S: K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 323: 561-565, 1990.
12. Sugio K, Ishida T, Yokoyama H, Inoue T, Sugimachi K and Sasazuki T: Ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis. Cancer Res 52: 2903-2906, 1992.
13. Kern JA, Slebos RJC, Top S, Rodenhuis S, Lager D and Robinson RA: C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. J Clin Invest 93: 516-520, 1993.
14. Mills NE, Fishman CL, Rom WN, Dubin N and Jacobson DR: Increased prevalence of K-ras oncogene mutations in lung adenocarcinoma. Cancer Res 55: 1444-1447, 1995.
15. Rosell R, Li S, Skacel Z, Mate JL, Maestre J, Canela M, Tolosa E, Armengol P, Barnadas A and Ariza A: Prognostic impact of mutated K-ras gene in surgically resected non-small-cell lung cancer patients. Oncogene 8: 2407-2412, 1993.
16. Rodenhuis S and Slebos RJC: Clinical significance of ras oncogene activation in human lung cancer. Cancer Res (Suppl) 52: 2665-2669, 1992.
17. Mountain CF: A new international staging system for lung cancer. Chest (Suppl) 89: 225-233, 1986.
18. Sobin LH: The World Health Organization's histological classification of lung tumors: a comparison of the first and second editions. Cancer Detect Prev 5: 391-406, 1982.
19. Blin N and Stafford DW: A general method for isolation of high molecular weight DNA from eukaryotes. Nucl Acids Res 3: 2303-2308, 1976.
20. Lin SY, Chen PH, Wang CK, Liu JD, Siauw CP, Chen YJ, Yang MJ, Liu MH, Chen TC and Chang JG: Mutation analysis of K-ras oncogenes in gastroenterologic cancers by the amplified created restriction method. Am J Clin Pathol 100: 686-689, 1993.
21. Sanger F, Nicklen S and Coulson AR: DNA sequencing with chain terminating inhibitors. Proc Natl Acad Sci USA 74: 5463-5467, 1977.
22. Sugio K, Kishimoto Y, Virmani AK, Hung JY and Gazdar AF: K-ras mutations are a relatively late event in the pathogenesis of lung carcinomas. Cancer Res 54: 5811-5815, 1994.
23. Urosevic N, Krtolica K, Skaro-Milic A, Knezevic-Usaj S and Dujic A: Prevalence of G to T transversions among K-ras oncogene mutations in human colorectal tumors in Yugoslavia. Int J Cancer 54: 249-254, 1993.
24. Moerkerk P, Arends JW, Van Driel M, de Bruïne A, de Goeij A and ten Kate J: Type and number of Ki-ras point mutations relate to stage of human colorectal cancer. Cancer Res 54: 3376-3378, 1994.
25. Giaretti W, Pujic N, Rapallo A, Nigro S, DiVinci A, Geido D and Risio M: K-ras-2 G→C and G→T transversions correlate with DNA aneuploidy in colorectal adenomas. Gastroenterology 108: 1040-1047, 1995.
26. Seeburg PH, Colby WW, Capon DJ, Goedel DV and Levinson AD: Biological properties of human c-Ha-ras-1 genes mutated at codon 12. Nature 312: 71-75, 1984.